Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313833 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness of Buprenorphine Transdermal System in Elderly Subjects With Chronic Pain: Pilot Study.
A Phase 3 study, sponsored by Purdue Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT00313833 is a Phase 3 study that has completed, run by Purdue Pharma. The registered enrollment target is 100 participants.
The verdict
NCT00313833, a Phase 3 study, has completed, sponsored by Purdue Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
This pilot study was designed to evaluate the effectiveness and tolerability of the buprenorphine transdermal system versus placebo on health outcomes in elderly residents in supervised living environments. The treatment intervention duration is 42 days during which time supplemental analgesic medication (usual analgesic care) will be provided to all subjects in addition to study drug.
Interventions
- DRUG Buprenorphine transdermal delivery system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2000-12 |
| Est. Completion | 2001-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00313833
The ClinicalTrials.gov registry entry for NCT00313833 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Purdue Pharma, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Buprenorphine transdermal delivery system is the first listed.
NCT00313833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00313833 about?
NCT00313833 is a clinical study titled "Safety and Effectiveness of Buprenorphine Transdermal System in Elderly Subjects With Chronic Pain: Pilot Study.". This pilot study was designed to evaluate the effectiveness and tolerability of the buprenorphine transdermal system versus placebo on health outcomes in elderly residents in supervised living environments. The treatment intervention duration is 42 days during which time supplemental analgesic medic...
What is the current status of trial NCT00313833?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2000-12. Estimated completion is 2001-11.
What interventions are being tested in trial NCT00313833?
The interventions under investigation include: Buprenorphine transdermal delivery system (DRUG).
Who is sponsoring clinical trial NCT00313833?
This trial is sponsored by Purdue Pharma, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.